Prostate Cancer

In a special article published online April 1 in Advances in Radiation Oncology, a framework is laid out for the management of radiotherapy for prostate cancer patients during the coronavirus disease 2019 (COVID-19) pandemic. Nicholas G. Zaorsky, M.D., from Penn State Cancer Institute in Hershey, and colleagues established recommendations and developed a Remote visit, and Avoidance,...

Prostate cancer incidence rates decreased from 2005 to 2016 for local-stage disease among men aged ≥50 years but increased for regional- and distant-stage disease, according to a study published online May 20 in the Journal of the National Cancer Institute. Ahmedin Jemal, D.V.M., Ph.D., from the American Cancer Society in Atlanta, and colleagues examined trends...

National, race-based differences in prostate cancer survival are due to regional variation, even for low-risk prostate cancer, according to a study published online March 31 in JAMA Network Open. Sean A. Fletcher, M.D., from Brigham and Women’s Hospital in Boston, and colleagues analyzed data from 17 geographic registries within the Surveillance, Epidemiology, and End Results database...

For men with advanced prostate cancer, the oral gonadotropin-releasing hormone (GnRH) antagonist relugolix maintains testosterone suppression compared with the GnRH agonist leuprolide, while enzalutamide is associated with improved survival versus placebo in nonmetastatic, castration-resistant prostate cancer, according to two studies published online May 29 in the New England Journal of Medicine to coincide with the American Society...

Prostate cancer clinical trial participants are overwhelmingly white, according to a study published online June 5 in Cancer Epidemiology, Biomarkers & Prevention. Emily M. Rencsok, from the Harvard T.H. Chan School of Public Health in Boston, and colleagues analyzed 72 global phase III and IV prevention, screening, and treatment prostate cancer clinical trials with enrollment start...

A large multi-national study analyzing data from 1993-2013 has concluded that minority underrepresentation is a recurring problem in clinical trials for novel agents to treat prostate cancer. This may have implications in clinical efficacy in minority populations while using those novel agents that were approved based on these under representative studies. Prostate cancer (PCa) incidence...

A 2018 study from the state of California found that the state’s Latino population was less likely to receive guideline recommended definite treatment for prostate cancer compared to Non-Latino white men. Latinos are the largest minority in the state of California, making up 39% of the state population. There has been a lack of information...

According to The Daily, Case Western Reserve University researchers revealed cellular distinctions between black and white patients with prostate cancer, using artificial intelligence. The team reported in a recent study that AI analysis of digitized images of cancer tissues show critical variations between black and white male prostate cancer patients. The findings indicate that the...

A retrospective study recently published in Cancer Medicine states that use of statins as monotherapy or with metformin is linked with lower mortality among men with high-risk prostate cancer. “Both metformin and statins have been associated with longer life [among men with] prostate cancer, yet because they are commonly prescribed together, no study we know...